NEW YORK (GenomeWeb News) – Reporting for the first time as a public company, BG Medicine reported after the close of the market on Wednesday that its fourth-quarter revenues fell 47 percent year over year, which it attributed to a reduction in the number of projects completed under its service agreements.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.